To evaluate 96-week virologic, immunologic, resistance and metabolic outcomes of bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) in antiretroviral therapy (ART)-naïve people li
Data from Genotypic Resistance Results Form [CRF 3, codon mutation identification table (PT/PI)] Study Description A randomized, proof-of-concept study of adolescents and young adults aged 18-24 years